Many MindedSpironolactone Shows Promise for Post-Stroke Blood Pressure Control
A Brazil-based trial (OPTIMAL-STROKE) found patients receiving spironolactone within 24 hours of stroke had significantly higher rates of achieving blood pressure <130/80 mmHg at three months compared to standard care. This effect appears clinically meaningful: a 7 mmHg systolic reduction correlates with 38% lower risk of recurrent stroke. However, one-third of stroke patients fail to meet blood pressure guidelines, and one in five discontinue antihypertensive medication within a year. The trial also revealed electrolyte changes consistent with diuretic use, requiring kidney function monitoring. Crucially, similar spironolactone targeting (<120 mmHg) showed no cardiovascular benefit for diabetes patients in a parallel trial (OPTIMAL-DIABETES), highlighting patient-specific responses. While spironolactone is widely available, its effectiveness depends on medical supervision—a critical barrier for millions who face inconsistent care. The unpublished REDUCE trial suggests potential utility but lacks formal validation. This evidence underscores how post-stroke blood pressure management remains a friction point: the same treatment that could reduce stroke recurrence also requires complex monitoring many cannot access. What to watch: Whether real-world implementation addresses kidney function monitoring and medication adherence gaps, especially in resource-limited settings where one-third of patients miss targets. The source material is brief and does not detail implementation barriers or cost implications.
Source: STAT